AstraZeneca gains CDSCO approval for treatment of muscle-invasive bladder cancer EP News Bureau Jul 15, 2025 Durvalumab in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Durvalumab as adjuvant…
